References
- Mills B, Yepes A, Nugent K. Synthetic cannabinoids. Am J Med Sci. 2015;350(1):59–62.
- Le Boisselier R, Alexandre J, Lelong-Boulouard V, et al. Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther. 2017;101(2):220–229.
- Smith JP Sutcliffe OB, Banks CE. An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). Analyst. 2015;140(15):4932–4948.
- UNODC World Drug Report 2020 [Internet]. United Nations: World Drug Report 2020. 2020. [cited 12 August 2021]. Available at: wdr.unodc.org/wdr2020/en/index2020.html
- Manthey J, Kilian C, Carr S, et al. Use of alcohol, tobacco, cannabis, and other substances during the first wave of the SARS-CoV-2 pandemic in Europe: a survey on 36,000 european substance users. Subst Abuse Treat Prev Policy. 2021;16(1):36.
- van Laar MW, Oomen PE, van Miltenburg CJA, et al. Cannabis and COVID-19: Reasons for concern. Front Psychiatry. 2020;11:601653.
- Infodrog. Alertes actuelles – Centrale nationale de coordination des addictions [Internet]. 2021. [cited 3 June 2021]. Available at: https://www.infodrog.ch/fr/aide/alertes-actuelles.html
- CEIP-A. Information – alerte relative aux cannabinoîdes de synthèse et risques [Internet]. 2020. [cited 3 June 2021]. Available at: http://www.dicadd13.fr/images/boiteaoutils/alerteCEIPcannabis.pdf
- OFDT. Circulation d’herbe de cannabis adultérée avec des cannabinoîdes de synthèse [Internet]. 2021. [cited 3 June 2021]. Available at: https://www.ofdt.fr/BDD/sintes/ir_19102020_Cannabis.pdf
- Morais JD, Brandt S, Jorge R, et al. EMCDDA technical report on the new psychoactive substance methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (MDMB-4en-PINACA).
- EMCDDA initial report on the new psychoactive substance MDMB-4en-PINACA | www.emcdda.europa.eu. [Internet]. 2021. [cited 3 June 2021]. Available at: https://www.emcdda.europa.eu/publications/initial-reports/mdmb-4en-pinaca_sl
- Krotulski AJ, Cannaert A, Stove C, et al. The next generation of synthetic cannabinoids: Detection, activity, and potential toxicity of pent‐4en and but‐3en analogues including MDMB‐4en‐PINACA. Drug Test Anal. 2021;13(2):427–438.
- Potts AJ, Cano C, Thomas SHL, et al. Synthetic cannabinoid receptor agonists: classification and nomenclature. Clin Toxicol (Phila). 2020;58(2):82–98.
- Logan BK, Mohr ALA, Friscia M, et al. Reports of adverse events associated with use of novel psychoactive substances, 2013-2016: a review. J Anal Toxicol. 2017;41(7):573–610.
- Jouanjus E, Gibaja V, Kahn J-P, et al. Signal identification in addictovigilance: the functioning of the french system. Therapie. avr. 2015;70(2):113–131.
- Persson HE, Sjöberg GK, Haines JA, et al. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36(3):205–213.
- ElSohly MA, Gul W, Wanas AS, et al. Synthetic cannabinoids: Analysis and metabolites. Life Sci. 2014;97(1):78–90.
- Pike E, Grafinger KE, Cannaert A, et al. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays: Part I-Synthesis, analytical characterization, and binding affinity for human CB1 receptors. Drug Test Anal. 2021;13(7):1383–1401.
- Castaneto MS, Gorelick DA, Desrosiers NA, et al. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41.
- Cannaert A, Storme J, Franz F, et al. Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay. Anal Chem. 2016;88(23):11476–11485.
- Pasin D, Cawley A, Bidny S, et al. Current applications of high-resolution mass spectrometry for the analysis of new psychoactive substances: a critical review. Anal Bioanal Chem. 2017;409(25):5821–5836.
- Lapeyre-Mestre M, Boucher A, Daveluy A, et al.; French Addictovigilance Network. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapies. juill. 2020;75(4):343–354.
- Rianprakaisang T, Gerona R, Hendrickson RG. Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient. Clin Toxicol. 2020;58(3):215–216.
- Lam RPK, Tang MHY, Leung SC, et al. Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations. Clin Toxicol (Phila)). 2017;55(7):662–667.
- Horth RZ. Acute poisonings from a synthetic cannabinoid sold as cannabidiol — Utah, 2017–2018. MMWR Morb Mortal Wkly Rep [Internet]. 2018. [cited 3 June 2021]; 67. Available at: https://www.cdc.gov/mmwr/volumes/67/wr/mm6720a5.htm
- EMCDDA. European Drug Report. 2020.
- WHO, Critical Review Report, MDMB-4en-PINACA [Internet]. 2021. [cited 3 June 2021]. Available at: https://www.who.int/docs/default-source/controlled-substances/43rd-ecdd/mdmb-4en-pinaca-review-2020.pdf?sfvrsn=5cd6e97e_4.
- Taylor M. Police Warn of Heroin Cut with Research-only Cannabinoid [Internet]. 2021. [cited 3 June 2021]. Available at: http://www.forensicmag.com/561307-Police-Warn-of-Heroin-Cut-with-Research-only-Cannabinoid/.
- Banister SD, Longworth M, Kevin R, et al. Pharmacology of valinate and tert-Leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci. 2016;7(9):1241–1254.
- Gurney SMR, Scott KS, Kacinko SL, et al. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev. janv. 2014;26(1):53–78.
- Hess C, Schoeder CT, Pillaiyar T, et al. Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicol. 2016;34(2):329–343.
- Pacher P, Steffens S, Haskó G, et al. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2018;15(3):151–166.
- Robson H, Braund R, Glass M, et al. Synthetic cannabis: adverse events reported to the New Zealand pharmacovigilance Centre. Clin Toxicol (Phila). 2021;59(6):472–479.
- Choi NG, Marti CN, DiNitto DM, et al. Cannabis and synthetic cannabinoid poison control center cases among adults aged 50+, 2009-2019. Clin Toxicol (Phila). 2021;59(4):334–342.
- Darke S, Duflou J, Farrell M, et al. Characteristics and circumstances of synthetic cannabinoid-related death. Clin Toxicol (Phila). 2020;58(5):368–374.
- Arens AM, Olives TD, Simpson NS, et al. An outbreak of synthetic cannabinoid exposures reported to a regional poison center: "K2" identified as 5F-ADB. Clin Toxicol (Phila). 2019;57(1):69–71.